FibroGen, Inc.

FibroGen, Inc.verified

FGEN

Price:

$1.06

Market Cap:

$105.44M

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopath...[Read more]

Industry

Biotechnology

IPO Date

2014-11-14

Stock Exchange

NASDAQ

Ticker

FGEN

The PE Ratio as of June 2024 (TTM) for FibroGen, Inc. (FGEN) is -0.43

According to FibroGen, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.43. This represents a change of -47.03% compared to the average of -0.81 of the last 4 quarters.

FibroGen, Inc. (FGEN) Historical PE Ratio (quarterly & annually)

How has FGEN PE Ratio performed in the past?

The mean historical PE Ratio of FibroGen, Inc. over the last ten years is -20.00. The current -0.43 PE Ratio has changed 115.01% with respect to the historical average. Over the past ten years (40 quarters), FGEN's PE Ratio was at its highest in in the December 2018 quarter at 46.99. The PE Ratio was at its lowest in in the June 2018 quarter at -55.90.

Quarterly (TTM)
Annual

Average

-20.00

Median

-19.52

Minimum

-48.27

Maximum

-0.30

FibroGen, Inc. (FGEN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of FibroGen, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 148.45%

Maximum Annual PE Ratio = -0.30

Minimum Annual Increase = -94.03%

Minimum Annual PE Ratio = -48.27

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.30-94.03%
2022-5.0813.50%
2021-4.47-74.59%
2020-17.61-63.53%
2019-48.277.24%
2018-45.0264.22%
2017-27.4125.93%
2016-21.771.57%
2015-21.43148.45%
2014-8.63-87.61%

FibroGen, Inc. (FGEN) Average PE Ratio

How has FGEN PE Ratio performed in the past?

The current PE Ratio of FibroGen, Inc. (FGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.29

5-year avg

-15.15

10-year avg

-20.00

FibroGen, Inc. (FGEN) PE Ratio vs. Peers

How is FGEN’s PE Ratio compared to its peers?

FibroGen, Inc.’s PE Ratio is greater than Ardelyx, Inc. (-22.28), greater than Zura Bio Limited (-3.40), less than Hepion Pharmaceuticals, Inc. (-0.14), less than AVROBIO, Inc. (2.16), greater than Verastem, Inc. (-0.88), greater than Mereo BioPharma Group plc (-84.65), greater than Blueprint Medicines Corporation (-22.19), greater than Agios Pharmaceuticals, Inc. (-6.81), greater than Day One Biopharmaceuticals, Inc. (-4.99), less than BioMarin Pharmaceutical Inc. (78.16), greater than Lyell Immunopharma, Inc. (-2.42), greater than Cullinan Oncology, Inc. (-6.18), greater than Monte Rosa Therapeutics, Inc. (-1.63), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-12.62), greater than Biomea Fusion, Inc. (-1.44), greater than Stoke Therapeutics, Inc. (-6.65), greater than Akero Therapeutics, Inc. (-7.58), less than Homology Medicines, Inc. (-0.01), greater than Gossamer Bio, Inc. (-0.68), greater than Vaxcyte, Inc. (-18.38), greater than Larimar Therapeutics, Inc. (-9.49), greater than Syndax Pharmaceuticals, Inc. (-7.04), greater than Merus N.V. (-21.65), greater than Sutro Biopharma, Inc. (-1.71),

Build a custom stock screener for FibroGen, Inc. (FGEN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like FibroGen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

FibroGen, Inc. (FGEN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like FibroGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is FibroGen, Inc.'s PE Ratio?

How is the PE Ratio calculated for FibroGen, Inc. (FGEN)?

What is the highest PE Ratio for FibroGen, Inc. (FGEN)?

What is the 3-year average PE Ratio for FibroGen, Inc. (FGEN)?

What is the 5-year average PE Ratio for FibroGen, Inc. (FGEN)?

How does the current PE Ratio for FibroGen, Inc. (FGEN) compare to its historical average?